Description: Under long-duration targeted improvements (LDTI), there are a few insurance liability balances that now are required to be fair valued, market risk benefit (MRB). The session will start from all the applicable balances that are required to be fair valued under LDTI ((i.e., MRB, financial accounting statement (FAS) 133, value of business acquired (VOBA) upon business combination)). The session will use a case study to discuss some of the nuances and general considerations for an MRB, FAS 133 and VOBA balances for a business combination for an fixed indexed annuity (FIA) contract. The case study will discuss some MRB fair value considerations and followed by FAS 133 fair value techniques. It will go over VOBA fair value estimation by using actuarial appraisal method with a few twists (e.g., using market yield in generating distributable earnings is better than using book yield and adjusted to bring it to fair value later on).

Description: Suited for students, newly minted ASAs/FSAs, or those venturing into the realm of reserving, as well as seasoned actuaries in need of a recap, this session is a gateway to the mysteries of IBNR reserving, unraveling various methods and assumptions. Embark on a journey through the construction of claims triangles and the crafting of completion factors, delving into the enigmatic realms of seasonality, trend analysis, and outlier claims. Harness the principles unveiled to dissect a myriad of case studies spanning diverse products like major medical inpatient, outpatient, pharmacy, Medicare Supplement, dental, and critical illness. This session is your guide through the intricate world of reserving!

Description: Generally accepted accounting practices (GAAP) reporting frameworks are more involved than ever before. From disclosures, to assumption changes, to interest rate movements, uncovering the drivers of income emergence can prove hard to do, and even trickier to communicate. This session will revisit how the updated standards create layers of complexity and offer ways to side step these obstacles to generate useful earnings analysis by various drivers.

Description: In this webinar, the presenters will give a behind the scenes look at how the NAIC ESG was parameterized. They will also share the results of its most recent calibration.

Description: With higher interest rates and aging populations, the Bermuda offshore reinsurance market has been heating up, particularly to firms backed by asset management firms and private equity. Increased competition along with changing regulatory requirements, and evolving expectations around model governance have actuaries facing heavier production and results explanation workloads. This creates additional challenges on top of an already complex Bermuda reporting regime, particularly with the Scenarios-Based Approach (SBA) and Bermuda Solvency Capital Requirement (BSCR).

Description: "This session is for liability-side actuaries seeking a summary of asset valuation principles. Topics to be discussed include: Why it's important in today's world to understand both sides of the balance sheet. Yield curves, including spot rates, forward rates, coupon rates and bootstrapping. Duration calculations, including an explanation of modified duration for contracts with embedded options and key rate durations. A summary of today's regulatory environment in the context of embedded options, including MRB, VM-21 and VM-22. Next, we will dive into duration profiles of different asset classes, including CLOs (floating rate), RMBS (negative convexity), traditional bonds and swaps. Lastly, we will discuss risk-neutral scenarios, martingale tests, and applications in hedging MRBs."

Description: In recent years, there has been a significant increase in life and annuity business transactions transferring blocks of business across jurisdictions. These transactions raise important questions for stakeholders-including policyholders, regulators, rating agencies, investors, and companies themselves-about the drivers of financial results under different regulatory and accounting regimes.As financial reporting frameworks grow more complex-whether US Statutory, IFRS 17, US GAAP, or Solvency II-stakeholders are demanding deeper insights into how results are determined and how they compare across jurisdictions. Understanding these differences is critical for assessing financial performance, capital strength, and risk exposures, particularly in a cross-border context.To address this need, many companies are developing and applying bridging analyses-such as waterfall analyses, step-by-step reconciliations, and other frameworks-to explain how and why results differ between reporting bases. These approaches help clarify key drivers and provide transparency to stakeholders.In this session, representatives from leading companies will share practical approaches they use to bridge these gaps, offering insights into the methodologies and analyses that have proven most effective in navigating cross-jurisdiction financial reporting challenges. Attendees will gain a clearer understanding of cross-jurisdiction reporting differences and take away ideas for applying effective bridging techniques within their own organizations.

Description: This project enhances the current understanding of cyber risks in the smart home ecosystem from the insurance industry's perspective. In particular, the quantitative framework and pricing strategies developed in this project can be immediately adopted/adapted by actuaries to price the cyber risks for smart homes, a fast-growing insurance market.

Description: Actuaries historically modeled new launches in pharmaceuticals by anticipating the expected change to the market basket. This became more complicated with the recent launches of gene and cell therapies as they address rare diseases. Rare conditions have low total member volume to study and some do not currently have a diagnosis code to identify them within claims data. Addressing this modeling challenge has been growing more important in the recent years with the number of therapies launching. What has the health care industry, and more specifically health care, done to enhance modeling and how should this be altered for the future? Additionally, historic modeling has sometimes incorporated a level of direct medical treatment cost offsets where studies have shown lower treatment costs are achievable. Can gene and cell financial modeling include cost offsets as well? And if so, what are suggested precautions or limitations to this effort?

Description: Renal disease is a very heterogenous medical condition whose end state is dialysis, a recurring cost intensive medical condition. Dialysis cost is one of the major medical cost drivers in USA. Insufficient and improper care management in the early stages of CKD (chronic kidney disease) leads to early incidence of end stage renal disease (ESRD) among CKD patients which not only leads to high medical costs, but also reflects poor health quality.